ĭemographic findings and underlying diseases of patients with vitamin D deficiency No.In some cases, yes.
A prospective study with 40 infants and toddlers in Qatar reported that parenteral injection of a megadose (10,000 IU/kg) of vitamin D3 for 3 months normalized all the laboratory findings and radiological manifestations. reported that a loading dosage of 20,000–40,000 IU of vitamin D 3 once a week, with a daily maintenance dosage of 4,000–6,000 IU/day on the remaining 6 days, has shown efficiency in improving the vitamin D level of 3 patients with intestinal failure. Additionally, a smaller number of patients still do not respond to a high amount of vitamin D 3. Previously, 10%–20% of patients with intestinal failure were reported to require daily oral vitamin D 3 at a dosage of 5,000–6,000 IU. Recent guidelines do not recommend stoss therapy as first-line management of vitamin D deficiency however, stoss therapy might be more practical for those who are noncompliant with daily dosing and those with intestinal malabsorption. showed that hypercalciuria and hypercalcemia have been more often described in children receiving stoss therapy. reported that 100,000 IU of oral cholecalciferol weekly for 4 weeks is as safe and effective as 5,000 IU oral cholecalciferol daily for 80 days in children older than 2 years. One retrospective cohort study of 61 children with rickets revealed that a single intramuscular injection of 600,000 IU vitamin D 3 and a weekly oral dosage of 60,000 IU vitamin D 3 for 10 weeks were equally effective and safe. Several studies were conducted to investigate the efficacy of a single, large dose of oral or intramuscular vitamin D, which was called "stoss therapy," for better convenience and compliance with therapy ( Table 4).
However, various treatment regimens have been proposed to treat vitamin D deficiency in children, including daily or weekly dosing for varied periods. In the present study, all patients were treated with 50,000 IU of parenteral vitamin D3 weekly.
0 kommentar(er)
